Heart disease remains the leading cause of death worldwide. Nearly 50% of adult Americans have elevated blood pressure, close to 80% of whom are not adequately controlled, leaving them at increased morbidity and mortality risk.
Source: ACC/AHA 2017 Hypertension Clinical Practice Guideline NHANES 2017 - March 2020
.jpg)
adapted from https://millionhearts.hhs.gov
BP control status
Recommended intervention
In light of this high unmet need more effective treatment options are needed for patients whose hypertension remains uncontrolled while on existing medications. Every 10 mm Hg reduction in systolic BP significantly reduces the risk of major cardiovascular events, including coronary heart disease, stroke, heart failure, and all-cause mortality.This highlights the need for novel, effective, and well-tolerated treatment options to help bring more patients to target and reduce their risk for morbidity and mortality associated with residual hypertension.
In light of this high unmet need more effective treatment options are needed for patients whose hypertension remains uncontrolled while on existing medications. Every 10 mm Hg reduction in systolic BP significantly reduces the risk of major cardiovascular events, including coronary heart disease, stroke, heart failure, and all-cause mortality.This highlights the need for novel, effective, and well-tolerated treatment options to help bring more patients to target and reduce their risk for morbidity and mortality associated with residual hypertension.
Retension Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing effective treatments for hypertension and cardiovascular health.
RTN-001 Mechanism of Action
RTN-001, Retension Pharmaceuticals’ lead compound, is a first-in-class, tissue-targeted PDE5 inhibitor that has been optimized to function in the central pulmonary vasculature for the treatment of hypertension. RTN-001 acts via cGMP by potentiating the action of nitric oxide (NO), which is essential in the control of vasodilation and blood pressure by a differentiated mechanism of action.
